Two-week intensive brain-focused therapy program for children with neurodevelopmental and chromosomal conditions
Official title: Functional and Neurodevelopmental Outcomes Following Intensive Multimodal Neurorehabilitation in Pediatric Patients With Neurodevelopmental Disorders, Including Chromosomal Abnormalities
Run by Healing Hope International · NCT07493096 · Data updated 2026-11-12
This program will try a two-week, individualized multimodal neurorehabilitation approach for children about 4–12 years old with neurodevelopmental or chromosomal conditions to see if it improves attention, motor skills, communication, and daily functioning.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 4 Years to 12 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Healing Hope International Academic / other |
| Locations | 1 site (The Woodlands, Texas) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | January 1, 2028 |
| Study ends | December 30, 2036 |
| Registry record updated | March 25, 2026 |
| Trial ID | NCT07493096 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children approximately 4–12 years old with neurodevelopmental, neurologic, or genetic/chromosomal diagnoses who have measurable functional impairments and can attend an in-person two-week intensive therapy schedule.
✕Probably not a fit
Children outside the age range, those who cannot tolerate or attend intensive in-person therapy (for example due to medical instability, uncontrolled seizures, or severe behavioral challenges), or those without target functional impairments are less likely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective observational characterization of outcomes for pediatric participants enrolled in a two-week intensive multimodal neurorehabilitation program. Children attend approximately 2.5 hours per day, five days per week, for two consecutive weeks, receiving individualized combinations of therapies such as sensory integration, motor planning, reflex integration, oculomotor training, executive function activities, communication supports, and adjunctive modalities. No randomization or experimental intervention is introduced; all therapies are delivered as part of routine clinical care and tailored to each child. Clinical and caregiver-reported measures are collected before and after the program to document functional and developmental changes.
Why it matters
Potential benefit: If successful, the program could improve attention, motor coordination, communication, emotional regulation, and day-to-day independence for participating children.
How similar studies have gone: Previous research on high-frequency, intensive pediatric neurorehabilitation (particularly motor-focused programs) has shown promising but mixed results, while evidence for adjunctive modalities like photobiomodulation and vibration therapy remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pediatric participants between approximately 4 and 12 years of age at the time of enrollment. * Diagnosed with or presenting with neurodevelopmental, neurologic, or genetic conditions, including but not limited to: * cerebral palsy * autism spectrum disorder * developmental delay * hypoxic ischemic encephalopathy (HIE) * traumatic brain injury * sensory processing disorder * chromosomal or genetic abnormalities * Demonstrate functional impairments in one or more neurodevelopmental domains, including: * motor coordination or motor planning * sensory processing * attention or executive functioning * oculomotor or visual processing * communication * emotional or behavioral regulation * activities of daily living * Enrolled in and able to participate in a two-week intensive therapy program consisting of approximately 2.5 hours per day/ 5 days per week * Able to complete baseline and post-program clinical assessment using clinician-observed or caregiver-reported measures. * Parent or legal guardian able to provide informed consent and participate in reporting functional outcomes when applicable. Exclusion Criteria: * Medical instability or acute medical condition that would prevent safe participation in an intensive therapy program. * Severe uncontrolled seizure activity or other neurologic condition that would interfere with participation in structured therapeutic activities, as determined by the treating clinician. * Behavioral or psychological conditions that would prevent safe engagement in the therapy environment despite appropriate support. * Inability to attend or complete the full two-week intensive program. * Lack of sufficient baseline or post-intervention data to assess change in functional performance. * Concurrent participation in another structured intervention or clinical study that would confound interpretation of functional outcomes, at the discretion of the investigator.
Where it's running
-
Ability and Beyond
The Woodlands, Texas, United States Recruiting
Study contacts
- Principal investigator: Dr. Tina Casoglos-Adamopoulos, OT, OTD, BCP — Board Certified Pediatric Therapist Executive Director Ability and Beyond Integrated Therapies
- Study coordinator: Genelle Mills, OTR/L
- Email: genelle@abilityandbeyond.com
- Phone: (480) 620-4514
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Assessing motor and voice development in infants
This study is trying to see if watching videos of infants can help spot early signs of physical disabilities, especially for those at risk of Cerebral Palsy, by looking at their movement and voice development.
-
Inclusive physical activity program for adults with intellectual disabilities
This study is testing a new fitness program for adults with intellectual disabilities to see if it helps them be more active and feel better over 16 weeks.
-
Leopard: using multi-omics to boost genetic diagnosis for neurodevelopmental disorders
This study tests a multi-omics approach to find genetic explanations for neurodevelopmental disorders in people with moderate-to-severe intellectual disability.
-
Non-invasive fetal cell test to check fetal chromosomal status in early pregnancy
A large, non-invasive blood test in pregnant people between 10 and 20 weeks looks for fetal cells in the mother's blood to see if the baby has certain chromosomal conditions, comparing results to invasive or postnatal diagnoses.
-
AdiaVita and glutathione for autism in kids and teens
This study tests whether adding AdiaVita (cord-blood stem cells and exosomes) to glutathione helps improve ASD symptoms in children and other participants compared with glutathione alone.
-
Online test of BlinkLab Dx1 for autism in kids aged 2–11
This study tests whether the BlinkLab Dx1 smartphone app can help identify autism in children aged 2 to 11 by comparing app-based measurements with prior clinical diagnoses.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.